The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:
----------
Powerhouse Energy Group PLC - Bingley, England-based hydrogen from waste plastic producer - Agrees variation to collaboration deals with Peel NRE Ltd. Exclusivity for deployment of distributed modular gasification technology extended to March 31. ‘Under this agreement, PHE granted Peel an option to enter into an exclusivity agreement with PHE in consideration of a payment to PHE of £500,000, superseding relevant terms set out in the collaboration agreement,’ Powerhouse Energy says. Loan facility with Protos Plastics, in which it has a 50% stake, to Hydrogen No1 Ltd extended to March 31.
----------
Red Rock Resources PLC - London-based natural resource development company with interests in Africa and Australia - Says seven hole reverse circulation drilling programme at Bilbale licence, Burkina Faso completed. ‘No ground geophysics was carried out, and we had to be guided by the pattern of previous artisanal activity and by the limited and large scale airborne geophysics in selecting the location of our drill holes,’ Red Rock says. ‘Given these limitations, that three holes of our first four drilled encountered gold and one intersected three gold mineralised zones including a high grade zone near surface is a happy circumstance, and offers great encouragement for the next stages of drilling which will follow detailed ground geophysics.’ Believes it has ‘exceptional portfolio of opportunities’ in Burkina Faso.
----------
Bradda Head Lithium Ltd - North America-focused lithium development company - Receives approval to drill at Basin East Extension, which lies adjacent to Basin East asset in Arizona. ‘Bradda Head has received permission to drill 120-holes at the company’s BEE State Lease. Drilling of the first phase (20 holes) is expected to commence in September,’ it explains.
----------
Synairgen PLC - Southampton, England-based drug discovery and biotechnology company - Collaborating in trial named Universal, alongside clinical trials unit of University of Southampton. Probe aims to improve knowledge nature of acute respiratory viral infection and recovery in patients admitted to hospital with respiratory symptoms. ‘The trial, which aims to recruit 1,000 patients, will be initiated at 10 sites across the UK following enrolment of its first patient which occurred on 1 September 2022. Viral testing equipment already owned by Synairgen and nursing staff at the Southampton clinical trial site are being provided by Synairgen, funding for the trial is being provided by Janssen,’ Synairgen says.
----------
Oakley Capital Investments Ltd - Investment vehicle - Invests in online legal information subscription platform vLex through Oakley Capital Origin Fund. Oakley Capital Investments says its direct contribution via Origin Fund will be around £8 million.
----------
Copyright 2022 Alliance News Limited. All Rights Reserved.
